Plasma Derived Therapy Market Size By Product (Coagulation Factors, Immunoglobulins, Albumin), By Application (Primary Immunodeficiency Diseases, Haemophilia, Idiopathic Thrombocytopenic Purpura (ITP)), Industry Analysis Report, Regional Outlook, COVID-19 Impact Analysis, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2030

Industry Overview

Plasma Derived Therapy Market size exceeded USD 17 billion in 2021 and is set to grow momentously at a 7.4% CAGR during the forecast period. Increasing prevalence of rare diseases including primary immunodeficiency diseases, idiopathic thrombocytopenic purpura (ITP), von Willebrand disease, and others are one of the major factors contributing to the business growth across the globe.
 

Get more details on this report - Request Free Sample PDF
 

According to the report published by the Centres for Disease Control and Prevention in 2021, around 3.2 million people in U.S. suffer from von Willebrand disease. Hence, the availability of effective plasma derived therapy that offers effective solution against these rare diseases will lead to unprecedented growth opportunities to the plasma derived therapy market in the forthcoming years.
 

The incidence of coronavirus infection has affected millions of individuals worldwide that had temporarily impacted the plasma donation globally, also affected the plasma derived therapy market. However, due to unavailability of specific treatment medicine and vaccine against COVID-19, research institutes have focused on plasma-based therapy to identify any role in treating the COVID-19.
 

Further, in March 2020, the Houston Methodist Hospital, U.S., announced use of plasma fractionation for treatment of COVID-19 and became the first hospital in U.S. to offer plasma derived therapy among COVID-19 patients. Therefore, high incidence rate of COVID-19 patients has resulted in increased demand for plasma derived immunoglobulins.
 

Plasma derived therapy is effective treatment derived from human plasma and widely used for the treatment of rare and complex diseases. Plasma-derived therapies help to replace deficient or missing proteins that allow people to lead more healthy and productive lives. The plasma-derived products majorly include coagulation factors, albumin and immunoglobulins that are used as life-saving therapeutics to treat several genetic, and life-threatening diseases globally.
 

Increasing research and development activities to develop plasma derived therapy against several diseases has driven the market statistics

Plasma industry is continuously investing in research and development activities to develop new plasma therapies leading to innovative treatments benefitting the patients. For instance, in March 2016, Grifols had invested USD 360 million in order to expand their production capabilities for plasma-derived therapies. This investment has helped company to enhance its place in the market coupled with its plasma fractionation capacity and purification facility.
 

Moreover, several other pharmaceutical and biotechnology companies had significant investment towards research and development to develop convalescent plasma therapy to treat critically ill COVID-19 patients. Additionally, favourable regulatory support to develop and commercialize plasma derived therapy is another factor benefiting the market growth. Thus, the aforementioned factors primarily drive the plasma derived therapy market share in 2021.
 

Growing number of patients suffering from primary immunodeficiency diseases will benefit the market expansion

Get more details on this report - Request Free Sample PDF
 

Based on the product, the immunoglobulin plasma derived product segment is projected to progress at a 7.3% CAGR from 2022 to 2030 due to increasing prevalence of primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disease (SID), Kawasaki disease (KD), immune thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN) and other neuromuscular conditions among population.
 

Immunoglobulin widely used to treat such conditions by replacing missing IgG serotype antibodies has driven its demand globally. According to the National Institute of Allergy and Infectious Diseases, over two hundred types of primary immunodeficiency diseases has affected around 500,000 population in the U.S. Thus, increasing prevalence such rare diseases will drive the plasma derived therapy market revenue.
 

Growing prevalence of haemophilia across the globe will augment the plasma derived therapy demand

Get more details on this report - Request Free Sample PDF
 

The application segment of plasma derived therapy market is classified into primary immunodeficiency diseases, haemophilia, idiopathic thrombocytopenic purpura (ITP) and others. Haemophilia is a rare bleeding disorder that restricts the normal blood clotting. The segment growth is attributed to increasing prevalence of haemophilia in developed and underdeveloped countries.
 

According to the data published by World Federation of Haemophilia in 2020, around 209,614 people are living with haemophilia across 120 countries in the world. Adding to this, haemophilia A is most prevalent type of condition. Therefore, growing prevalence of haemophilia coupled with large patient pool will significantly influence the plasma derived therapy demand during the analysis period to reach over USD 12.5 billion by the year 2030.
 

Presence of leading plasma derived therapy market players will drive the North America market size

Get more details on this report - Request Free Sample PDF
 

North America plasma derived therapy market held over 52% business share in 2021 and is projected to experience remarkable growth during the foreseeable future. Favourable government initiatives and expanding coverage of plasma collection centres by leading market players will offer growth opportunities to the market. Furthermore, increasing awareness about plasma derived therapies among blood donors, and favourable initiatives undertaken by major market players to stimulate blood donation in the region will accelerate the regional revenue growth.
 

Adding to this, U.S. market dominated the North America plasma derived therapy industry in 2021 with significant demand as well as high plasma volume in the region. Increase in number of patients with rare diseases has strengthened the growth potential of market players operating in the country.
 

Prominent industry players are focusing on strategic alliances that will drive the market growth

Some of the prominent business players operating in the plasma derived therapy industry include CSL Behring, Takeda Pharmaceutical Company Limited, Biotest AG, Octapharma, BPL, ADMA Biologics, Grifols, SA, Kedrion, Kamada Pharmaceuticals, SK Plasma, Pfizer, among others. These market players are adopting various inorganic growth strategies to gain market share and sustainable competitive advantage.
 

For instance, In April 2020, leading companies namely Bio Products Laboratory (BPL), Takeda Pharmaceutical Company Limited, Biotest AG, Octapharma, and CSL Behring collaborated to speed up the development of significant hyperimmune therapy against Covid-19.
 

Some of the recent industry developments:

• In July 2020, Grifols one of the leading plasma-derived medicines producer signed agreement with GC Pharma to acquire Montreal-based plasma fractionation facility along with other 11 U.S.-based plasma collection centres, and two purification facilities. This strategic move helped the company to enhance its market revenue along with maintaining its leading position in the industry
   
• In March 2020, Takeda Pharmaceutical Company Limited initiated the development process of anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)- TAK-888 for treating Corona Virus (COVID-19). Such initiatives undertaken by pharmaceutical companies accelerated the treatment development procedure against Covid-19. Thus, leading to effective disease management
   

The plasma derived therapy market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2030, for the following segments:

By Product

• Coagulation factors
• Immunoglobulins
• Albumin
• Others

By Application

• Primary immunodeficiency diseases
• Hemophilia
• Idiopathic thrombocytopenic purpura (ITP)
• Others

The above information is provided for the following regions and countries:

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Others
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Others
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Others